This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Flowr Past Earnings Performance

Past criteria checks 0/6

Key information

-49.7%

Earnings growth rate

-20.8%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate44.1%
Return on equity-740.2%
Net Margin-762.8%
Last Earnings Update30 Sep 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Flowr makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:2VX Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2212-95131
30 Jun 2213-99151
31 Mar 2212-84141
31 Dec 2112-86162
30 Sep 2110-118152
30 Jun 2110-120161
31 Mar 2110-122191
31 Dec 208-126221
30 Sep 206-47261
30 Jun 204-53311
31 Mar 204-36351
31 Dec 195-31331
30 Sep 198-14310
30 Jun 197-4260
31 Mar 194-19200
31 Dec 183-15150
30 Sep 180-11100
30 Jun 180-670
31 Mar 180-440
31 Dec 170-230

Quality Earnings: 2VX is currently unprofitable.

Growing Profit Margin: 2VX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2VX is unprofitable, and losses have increased over the past 5 years at a rate of 49.7% per year.

Accelerating Growth: Unable to compare 2VX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2VX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.2%).


Return on Equity

High ROE: 2VX has a negative Return on Equity (-740.24%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies